Drug Development Institute


Accelerating innovative research to speed cures to cancer patients

The Drug Development Institute (DDI) is a biotech-like institute embedded in The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). By bringing an industry-focused perspective to all investment and management decisions, the DDI ensures that programs have a high likelihood of progressing to clinical stage development. Our goal is to rapidly translate Ohio State’s most innovative research into tomorrow’s most promising treatments for patients with cancer.

The DDI employs a combination of targeted investments, strategic management and cutting-edge drug development resources to drive projects from discovery through early drug development, thus creating high-value new drug candidates.


The DDI was founded to address the translational development gap that exists between discoveries made in the research lab and the conversion of those discoveries to innovative drug therapies for patients. This gap is often due to a limitation in resources and the complexity of the drug-development process.

Read More


The DDI invests its resources in the most viable projects after a robust validation process. We understand that partnering with industry will bring new therapies to patients more quickly; therefore, we encourage partnering discussions at any stage of development (partnering zone).

Read More

DDI Team

The DDI is led by a team of highly experienced scientists.

Read More

Advisory Board

The DDI Advisory Board, which bolsters our strategic direction, consists of internationally recognized experts with proven track records in pharmaceutical drug discovery, development and commercialization.

Read More


The DDI is staffed by scientists with experience in the pharmaceutical industry at all stages of the drug development process and leverages world-class research, expertise and resources at Ohio State and externally to advance projects through preclinical development to clinical trials.

Read More

For Industry and Venture Capital Firms

The OSUCCC – James Drug Development Institute (DDI) partners with pharmaceutical, biotech and venture capital companies to bridge the gap between academic discovery and early clinical development, accelerating development timelines and delivering innovative treatments to patients sooner.

Read More

For Researchers

The Drug Development Institute (DDI) can accelerate your research project into new therapies for patients. Learn what makes a good drug development project, how to seek advice on developing a new therapy and how to apply for project support.

Read More

Success Stories

Since making its first investment in 2013, the DDI has achieved a number of key milestones and is making a significant impact on the drug development environment in Ohio.

Read More

Contact the DDI

Email: ddi@osumc.edu
Phone: 614-685-6957 

Meet Us

The DDI Team will be at the following conference.

AACR Annual Meeting

Atlanta, Ga.
March 30-April 3, 2019

Schedule a Meeting

Support the DDI

Donate Now